Summary
IDEXX Laboratories, Inc. (IDXX) has filed an 8-K report detailing the execution of an Amended and Restated Credit Agreement on March 30, 2007. This agreement amends and extends their existing revolving credit facility, increasing the total commitment to $125 million and extending the maturity date to March 30, 2012. This provides the company with enhanced financial flexibility for general corporate purposes and potential future investments or acquisitions. The agreement also includes an option to increase the aggregate commitments up to $250 million, subject to certain conditions, indicating the company's potential for future growth and capital needs. The facility is unsecured and involves multiple banking institutions, with interest rates tied to market benchmarks (LIBOR, CDOR, EURIBO) plus a margin based on the company's leverage ratio, and includes commitment fees on unused portions. This demonstrates a structured approach to managing debt and maintaining financial health.
Key Highlights
- 1IDEXX entered into an Amended and Restated Credit Agreement on March 30, 2007.
- 2The agreement establishes a five-year unsecured revolving credit facility totaling $125 million, maturing on March 30, 2012.
- 3The facility allows for an optional increase in commitments up to $250 million.
- 4Funds are available for general corporate purposes of IDEXX and its subsidiaries.
- 5Interest rates are variable, based on LIBOR, CDOR, or EURIBO, plus a margin tied to the company's consolidated leverage ratio.
- 6The agreement includes customary affirmative, negative, and financial covenants, including debt-to-EBITDA ratios.
- 7Key subsidiaries are listed as borrowers, and material U.S. subsidiaries are required to provide guarantees.